NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

$1.48

0.00 (0.00%)

(As of 06/1/2023 ET)

Compare

Today's Range: $1.48
▼
$1.48
50-Day Range: $1.43
▼
$1.98
52-Week Range: $0.82
▼
$3.88

Volume: N/A
Average Volume: 444,665 shs
Market Capitalization: $58.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.91

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 232.0% Upside
$4.91 Price Target
Short Interest: Healthy
1.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: 0.69
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$577,108 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.68) to ($0.79) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.28 out of 5 stars

Medical Sector

5th out of 983 stocks

Biological Products, Except Diagnostic Industry

2nd out of 164 stocks

4.1

Analyst's Opinion

Consensus Rating
TCR2 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.91, TCR2 Therapeutics has a forecasted upside of 232.0% from its current price of $1.48.
Amount of Analyst Coverage
TCR2 Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
1.15% of the float of TCR2 Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
TCR2 Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TCR2 Therapeutics has recently decreased by 15.89%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
TCR2 Therapeutics does not currently pay a dividend.
Dividend Growth
TCR2 Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
TCR2 Therapeutics has received a 75.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for TCR2 Therapeutics is -0.65.

3.2

News and Social Media Coverage

News Sentiment
TCR2 Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for TCR2 Therapeutics this week, compared to 1 article on an average week.
Search Interest
11 people have searched for TCRR on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added TCR2 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TCR2 Therapeutics insiders have bought 337.47% more of their company's stock than they have sold. Specifically, they have bought $577,108.00 in company stock and sold $131,920.00 in company stock.
Percentage Held by Insiders
25.01% of the stock of TCR2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.76% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TCR2 Therapeutics are expected to grow in the coming year, from ($2.68) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TCR2 Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

June 1, 2023 | finance.yahoo.com

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 1, 2023 | americanbankingnews.com

Kevin C. Tang Acquires 50,000 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

June 3, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 26, 2023 | americanbankingnews.com

Mpm Asset Management Llc Sells 70,170 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

May 26, 2023 | americanbankingnews.com

Comparing TCR2 Therapeutics (NASDAQ:TCRR) & Immunocore (NASDAQ:IMCR)

May 24, 2023 | americanbankingnews.com

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Receives $3.57 Consensus Target Price from Brokerages

May 16, 2023 | benzinga.com

TCR2 Therapeutics Insider Trades Send a Signal

May 12, 2023 | msn.com

Recap: TCR2 Therapeutics Q1 Earnings

June 3, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 12, 2023 | americanbankingnews.com

Kevin C. Tang Purchases 6,774 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

May 12, 2023 | americanbankingnews.com

Kevin C. Tang Purchases 57,073 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

May 11, 2023 | marketwatch.com

10-Q: TCR2 THERAPEUTICS INC.

May 11, 2023 | finance.yahoo.com

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023 | americanbankingnews.com

Insider Buying: TCR2 Therapeutics Inc. (NASDAQ:TCRR) Major Shareholder Acquires $320,300.16 in Stock

May 7, 2023 | americanbankingnews.com

Kevin C. Tang Buys 18,513 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock

May 1, 2023 | americanbankingnews.com

Brokerages Set TCR2 Therapeutics Inc. (NASDAQ:TCRR) PT at $3.57

April 23, 2023 | americanbankingnews.com

TCR2 Therapeutics (NASDAQ:TCRR) and Fate Therapeutics (NASDAQ:FATE) Head-To-Head Comparison

April 15, 2023 | finance.yahoo.com

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky

April 4, 2023 | americanbankingnews.com

Brokerages Set TCR2 Therapeutics Inc. (NASDAQ:TCRR) Target Price at $3.57

March 31, 2023 | americanbankingnews.com

Short Interest in TCR2 Therapeutics Inc. (NASDAQ:TCRR) Decreases By 19.4%

March 26, 2023 | americanbankingnews.com

Wedbush Reaffirms Neutral Rating for TCR2 Therapeutics (NASDAQ:TCRR)

March 26, 2023 | americanbankingnews.com

TCR2 Therapeutics' (TCRR) Hold Rating Reiterated at EF Hutton Acquisition Co. I

March 25, 2023 | msn.com

Mizuho Downgrades Tcr2 Therapeutics (TCRR)

March 25, 2023 | americanbankingnews.com

TCR2 Therapeutics' (TCRR) Neutral Rating Reiterated at Wedbush

March 24, 2023 | americanbankingnews.com

TCR2 Therapeutics (NASDAQ:TCRR) Rating Lowered to Neutral at Mizuho

March 23, 2023 | markets.businessinsider.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities

March 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)

See More Headlines

TCRR Price History

30 days | 90 days | 365 days | Advanced Chart

TCRR Company Calendar

Last Earnings: 3/23/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TCRR
CUSIP: N/A
CIK: 1750019
Web: www.tcr2.com
Phone: (617) 949-5200
Fax: N/A
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.91
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $1.68
Forecasted Upside/Downside: +232.0%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-151,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.81%
Return on Assets: -69.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.96
Quick Ratio: 2.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.58 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 39,260,000
Free Float: 29,443,000
Market Cap: $58.10 million
Optionable: Not Optionable
Beta: 1.95

Key Executives

Garry E. Menzel
President, Chief Executive Officer & Director

Peter Olagunju
Chief Operating Officer

Eric M. Sullivan
Chief Financial Officer

Alfonso Quintás-Cardama
Chief Medical Officer

Praveen Malhotra
Vice President-Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.
View TCRR analyst ratings or view top-rated stocks.
What is TCR2 Therapeutics' stock price forecast for 2023?: 8 analysts have issued twelve-month price targets for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they expect the company's share price to reach $4.91 in the next twelve months. This suggests a possible upside of 232.0% from the stock's current price.
View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts.
How have TCRR shares performed in 2023?: TCR2 Therapeutics' stock was trading at $0.9988 at the start of the year. Since then, TCRR shares have increased by 48.2% and is now trading at $1.48.
View the best growth stocks for 2023 here.
Are investors shorting TCR2 Therapeutics?: TCR2 Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 360,900 shares, a drop of 15.9% from the April 30th total of 429,100 shares. Based on an average daily volume of 602,700 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.2% of the company's shares are sold short.
View TCR2 Therapeutics' Short Interest.
When is TCR2 Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our TCRR earnings forecast.
How were TCR2 Therapeutics' earnings last quarter?: TCR2 Therapeutics Inc. (NASDAQ:TCRR) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.76.
What ETF holds TCR2 Therapeutics' stock ?: Harbor Disruptive Innovation ETF holds 18,131 shares of TCRR stock, representing 0.10% of its portfolio.
What other stocks do shareholders of TCR2 Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?: (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.
What is TCR2 Therapeutics' stock symbol?: TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."
Who are TCR2 Therapeutics' major shareholders?: TCR2 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.07%), Long Focus Capital Management LLC (1.44%), Renaissance Technologies LLC (1.13%), Citigroup Inc. (0.98%), Long Focus Capital Management LLC (0.91%) and Dimensional Fund Advisors LP (0.44%). Insiders that own company stock include Alfonso Quintas Cardama, Garry E Menzel, Kevin C Tang, Mayur Ian Somaiya, Mpm Asset Management Llc and Robert Hofmeister.
View institutional ownership trends.
How do I buy shares of TCR2 Therapeutics?: Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is TCR2 Therapeutics' stock price today?: One share of TCRR stock can currently be purchased for approximately $1.48.
How much money does TCR2 Therapeutics make?: TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $58.10 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.
How many employees does TCR2 Therapeutics have?: The company employs 137 workers across the globe.
How can I contact TCR2 Therapeutics?: TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial